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This text referring directly to the diagnosis and treatment of hypertension in elderly patients is a translation of a fragment of REMEDIA NT 65+ GP  
published in the “Lekarz POZ” (GP Practitioner) journal 4/2018.
Epidemiology of hypertension  
in the elderly
Hypertension, due to its high prevalence, remains 
the most important risk factor of premature deaths 
worldwide, also in elderly patients. There is a linear 
relationship between blood pressure (BP) and the 
mortality and incidence of cardiovascular diseases 
(myocardial infarction, stroke, peripheral artery dis-
ease) and renal failure in this age group, both in 
men and in women. In middle age-patients, systolic 
blood pressure better describes cardiovascular risk, 
and in elderly patients pulse pressure, i.e. the differ-
ence between the systolic and diastolic pressures, is 
an additional indicator of increased risk.
The incidence of hypertension increases with age; 
it affects around 10% of people aged 18–39 years, 
around 40% of those aged 40–59 years and exceeds 
65% in the 60–79 age group. Data from the last 20 
years indicate a continuous increase in the preva-
lence of hypertension in people aged 60–79 years 
in Poland. According to the NATPOL 2011 study, 
the prevalence of hypertension in this age group in-
creased from 55 to 64% in men and from 61 to 71% 
in women over the last 10 years — overall around 4 
million people. This is confirmed by data from the 
WOBASZ 2014 survey. Additionally, according the 
results of the POLSENIOR study, there are about 
1 million people with hypertension aged 80 years 
and older. If current trends persist, the number of 
patients with hypertension may increase by half by 
2035, provided that diagnostic criteria remain the 
same. In the United States, hypertension, currently 
defined as BP > 130/80 mm Hg, affects 76% of peo-
ple aged 65–74 and 82% of those aged 75 and older.
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Diagnosis of hypertension in patients 
over 65 years of age
The basis for the diagnosis of hypertension, also in 
the elderly, is properly performed BP measurement. 
Other examinations are used to assess cardiovascu-
lar risk and determine the cause of hypertension. 
Because the BP value is not constant, the required 
number of measurements and preferred methods of 
BP measurement depend on clinical situation. It is 
currently recommended to measure BP on the arm 
using a semi-automated auscultatory or oscillometric 
sphygmomanometer. The 2018 ESH/ESC Guide-
lines recommend prophylactic BP measurement ev-
ery 1–5 years depending on the BP level (optimal, 
normal or high normal). We recommend that in the 
elderly, the BP measurement should be performed 
every 6–12 months, because studies have shown that 
the 4-year rate of hypertension development is much 
higher in this age group.
Classification
Until recently, there was a consensus around the 
world about the classification of hypertension based 
on the cut-off BP value of 140/90 mm Hg dividing 
the population of adults into those with normal BP 
and hypertensives. Classifications of hypertension 
were very similar in the USA (the JNC 8 Hyperten-
sion Guidelines) and Europe (the 2013 ESH/ESC 
Guidelines), and the classification proposed by ESH/
ESC was adopted in European national recommen-
dations, also in Poland (2015 PTNT guidelines). In 
2017, the American guidelines (ACC/AHA High 
Blood Pressure Guidelines) were published which 
included a new classification of hypertension based 
on the cut-off value of 130/80 mm Hg, with 10–20 
mmHg lower thresholds for normal BP categories 
and degrees of hypertension. This new classification, 
having a huge impact on the initiation of antihyper-
tensive treatment and target BP values, i.e. the ag-
gressiveness of therapy, was not adopted in the 2018 
ESH/ESC Guidelines. Also in REMEDIA NT 65+ 
GP, we propose to keep using hypertension classifica-
tion based on office measurements, with three grades 
of hypertension, and a separate category for isolated 
systolic hypertension (ISH). This classification also 
comprises three categories for normal BP: optimal, 
normal and high-normal.
Detailed classification of hypertension is presented 
in Table I.
Diagnosis
Older age is not a reason to change the classifica-
tion of hypertension and the principles of the di-
agnosis of this disease. Hypertension is diagnosed 
if the mean BP values (calculated from at least two 
measurements made during at least two different 
visits) are equal to or higher than 140 mmHg for 
systolic blood pressure and/or 90 mm Hg for dia-
stolic blood pressure.
In patients with BP <160/100 mm Hg, diagnosis 
of hypertension should be confirmed by ambulatory 
blood pressure monitoring (ABPM) or, if it is not 
possible, by performing home BP measurements, 
adopting different normal values for these measure-
ments, as presented in Table II. This is particularly 
important in elderly patients, because they are char-
acterized by a high variability of BP due to vegetative 
dysfunction. Therefore, office measurements often 
do not reflect the real average BP values. In elderly 
patients, depending on their mental status, home 
measurements should be supervised or performed by 
family members.
In patients with BP ≥ 180/≥ 110 mm Hg it is ac-
ceptable to diagnose hypertension at the first visit, 
after excluding factors increasing blood pressure, 
such as anxiety, pain etc. Hypertension can also be 
diagnosed based on reliable data from patients’ his-
tory or medical records (high BP values or taking 
antihypertensive drugs).
Diagnostic challenges
Apart from the difficulties in diagnosing hyperten-
sion resulting from typical errors in the BP mea-
Table I. Classification of normal blood pressure and hypertension
Category Systolic blood pressure [mm Hg] Diastolic blood pressure [mm Hg]
Optimal < 120 and < 80
Normal 120–129 and/or 80–84
High normal 130–139 and/or 85–89
Grade 1 hypertension 140–159 and/or 90–99
Grade 1 hypertension 160–179 and/or 100–109
Grade 1 hypertension ≥ 180 and/or ≥ 110
Isolated systolic hypertension ≥ 140 and < 90
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surement technique (patient preparation, inappro-
priate cuff, bad arm position, etc.), which are not 
related to age, there are also diagnostic challenges 
typical of old age. In about 10% of older patients, 
a difference between BP values measured in the 
right and left arm exceeds 10 mm Hg. The afore-
mentioned vegetative dysfunction translates into 
orthostatic hypotension episodes (it is important 
to measure BP in supine and standing positions) 
and postprandial hypotension. Also, white coat 
phenomenon is more frequently observed in this 
group of patients.
Another diagnostic challenge in older people may 
be pseudo-hypertension, which is an overestimation 
of BP values in cuff measurements due to excessive 
stiffness of the brachial artery, often caused by its cal-
cification. Pseudo-hypertension should be suspected 
when very high BP values are recorded in the absence 
of organ complications. Osler’s manoeuvre has been 
recommended for identifying patients with pseudo-
hypertension.
Clinical evaluation
Diagnostic workup after detecting hypertension in 
elderly patients is identical to that in younger pa-
tients. Each patient should undergo a full clinical 
examination including detailed medical history and 
physical examination, with particular focus on po-
tential pathologies indicating secondary hyperten-
sion and the presence of organ-related complications. 
Other cardiovascular risk factors should be sought 
and in case of clinical suspicion, tests for organ dam-
age and other diseases should be performed, includ-
ing the assessment of cardiovascular system, in order 
to determine the cause of hypertension (searching for 
secondary forms of hypertension). Elderly patients 
are characterized by more frequent presence of car-
diovascular risk factors and concomitant diseases. It 
should be remembered that age itself is an important 
risk factor; therefore, when assessing global cardio-
vascular risk, higher risk level should be chosen in 
borderline situations.
The assessment of cognitive functions of the pa-
tient and, if necessary, tests aimed at detecting the 
features of dementia are particularly important in 
the elderly.
Laboratory tests
All elderly patients with hypertension should under-
go basic laboratory tests: blood counts, fasting glu-
cose, sodium and potassium levels, total cholesterol, 
HDL (high-density lipoprotein) cholesterol, LDL 
(low-density lipoprotein) cholesterol, triglycerides, 
creatinine concentration and estimated glomerular 
filtration rate, uric acid concentration, urinalysis, 
albuminuria and electrocardiogram.
Additional diagnostic tests should be performed 
in patients in whom medical history, physical exam-
ination or basic laboratory tests indicate the need 
for extended diagnostics including cardiac echocar-
diography, carotid and urethral ultrasound, assess-
ment of albuminuria and, in the case of a positive 
result, quantitative measurement of urinary protein 
excretion, assessment of 24h urinary sodium and 
potassium excretion, fundoscopy, oral glucose toler-
ance test (OGTT), ABPM, 24-hour ECG record-
ing in the event of arrhythmia, and evaluation of 
ankle-brachial index (ABI) and pulse wave velocity 
(PWV).
Diagnosis of secondary hypertension
The most common cause of secondary hypertension 
in the elderly is chronic kidney disease. However, pa-
tients in whom hypertension remained undiagnosed 
for a long time or was ineffectively treated, second-
ary kidney injury (hypertensive nephropathy) may 
occur, which should be differentiated from primary 
kidney injury. A relatively common cause of second-
ary hypertension in older patients is narrowing of 
one or both renal arteries due to atherosclerosis. In 
this situation, there is a sudden increase in the BP, 
resistance to treatment and accompanying deteriora-
tion of kidney function. In these patients complete 
diagnostic workup should be made according to 
generally accepted principles, bearing in mind that 
contrast imaging should be performed with caution 
and prophylaxis of contrast nephropathy should be 
provided.
Table II. Blood pressure (BP) thresholds for diagnosis of hypertension according to ambulatory or home measurements
Category Systolic blood pressure [mm Hg] Diastolic blood pressure [mm Hg]
Ambulatory BP
Daytime (or awake) ≥ 135 and/or ≥ 85
Night-time (or asleep) ≥ 120 and/or ≥ 70
24 h mean ≥ 130 and/or ≥ 80
Home BP ≥ 135 and/or ≥ 85
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Isolated systolic hypertension
Isolated systolic hypertension is defined as perma-
nently elevated systolic blood pressure (> 140 mm 
Hg) with normal diastolic blood pressure (< 90 mm 
Hg). It is the most prevalent form of hypertension 
in elderly patients. The pathogenesis of this type of 
hypertension is well established and is believed to be 
due to the reduction of elasticity and distensibility 
of the aorta and large arteries caused by increasing 
with age and progression of atherosclerosis deposi-
tion of calcium and collagen in the arterial wall, at 
the expense of elastin content. This leads to reduced 
“buffering” (increase in systolic BP) and “air-cham-
ber” functions (decrease in diastolic RR) of the aorta.
Although systolic blood pressure is the key param-
eter determining the cardiovascular risk, the reduced 
diastolic pressure is a pathophysiological factor de-
termining the so-called J curve, i.e. an increase in the 
risk of ischaemic heart disease with excessive decrease 
of diastolic BP. This has its therapeutic implication 
— striving for lowering systolic BP may be associated 
with the risk of excessive reduction of diastolic BP. 
This problem will be reflected below in the recom-
mendations regarding target BP values in patients 
with this type of hypertension. It is worth remem-
bering that antihypertensive drugs reduce both BP 
parameters proportionally and, despite between-drug 
differences in this respect, do not quickly affect the 
aortic compliance, a factor determining the increase 
in systolic BP and at the same time lowering the 
diastolic BP.
Thiazide-like diuretics and dihydropyridine cal-
cium antagonist are preferred in the treatment of iso-
lated systolic hypertension. This recommendation is 
based on the results of three clinical trials in patients 
with isolated systolic hypertension: SHEP (Systolic 
Hypertension in the Elderly Program), Syst-Eur 
(Systolic Hypertension in Europe) and HYVET 
(Hypertension in the Very Elderly Trial).
Treatment of hypertension
Criteria for initiating antihypertensive  
therapy
The consequence of the new classification of hy-
pertension proposed in the American 2017 ACC/ 
/AHA Guidelines is the change in the principles of 
pharmacological treatment of hypertension, also in 
elderly patients. American guideline recommend ini-
tiation of antihypertensive drug therapy when the BP 
is > 130/80 mm Hg These recommendations are also 
reflected in the change of the pharmacotherapy ini-
tiation criteria in the current European 2018 ESH/ 
/ESC Guidelines, despite the fact that they did not 
adopt the American classification. The 2018 ESH/ 
/ESC Guidelines, however, do not recommend such 
an early, „aggressive” introduction of antihyperten-
sive drug therapy in elderly patients.
Therefore, criteria for the initiation of antihyper-
tensive therapy suggested in the REMEDIA NT 65+ 
GP, which are presented in Table III, are based largely 
on the 2018 ESH/ESC 2018 Guidelines.
Blood pressure targets
One of the most discussed topics last year in anti-
hypertensive therapy was an attempt to question 
in most patients with hypertension the current BP 
target of < 140/90 mm Hg. This discussion was ini-
tiated after issuing the American 2017 ACC/AHA 
guidelines that recommend BP target of < 130/80 
mm Hg practically in all patients with hypertension, 
including the elderly. The basic argument for this ap-
proach is the data from a large, randomized SPRINT 
(Systolic Blood Pressure Intervention Trial) study, 
Table III. Initiation of antihypertensive therapy in elderly patients according to office blood pressure
Recommendation Class of recommendation Level of evidence
Lifestyle interventions are recommended in all patients aged > 65 years with SBP 
≥ 130/85 mm Hg (high normal BP)
I A
Pharmacotherapy of hypertension is recommended in fit patients aged 65–80 
years with SBP ≥ 140 mm Hg, provided that treatment is well tolerated
I A
Initiation of pharmacotherapy of hypertension is recommended in fit patients older 
than 80 years with SBP ≥ 160 mm Hg
I A
Initiation of pharmacotherapy of hypertension may be considered in patients 
with frailty syndrome (usually those older than 80 years) with SBP ≥ 160 mm Hg, 
provided that treatment is well tolerated
II B
Withdrawal of well-tolerated antihypertensive therapy when patients attain 
the age of 65 or 80 years, which is associated with lack of indications for drug 
therapy, is not recommended
III A
BP — blood pressure; SBP — systolic blood pressure
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in which treatment targeting systolic BP to < 120 
mmHg was associated with a reduction in the risk 
of death and/or cardiovascular disease by about 30% 
(including a sub-analysis of patients older than 75 
years of age) compared with the traditional BP target 
(< 140 mm Hg). As a consequence, some of the latest 
meta-analyses including the SPRINT study yielded 
similar conclusions. However, there are serious res-
ervations about the correctness of the conclusions 
drawn based on the SPRINT study due to the ap-
plied BP measurement procedure without the partic-
ipation of a physician, thus lowering the readings due 
to the elimination of the white coat phenomenon, 
and the accepted recruitment methodology resulting 
in in the majority of patients already using combina-
tion therapy and well adapted to low BP values.
These reservations are partly shared by the au-
thors of the 2018 ESH/ESC Guidelines, who recom-
mend in elderly patients, differently than in younger 
patients, systolic BP target of < 140 mm Hg, i.e. 
the previously used value, and not lower than 130 
mmHg, regardless of the level of cardiovascular risk 
and vascular complications, while lowering the di-
astolic BP target to < 80 mm Hg.
A much more cautious approach to the princi-
ples of initiating pharmacotherapy and blood pres-
sure targets has been adopted by the authors of the 
American College of Physicians and the American 
Academy of Family Medicine guidelines for the treat-
ment of hypertension in elderly patients published 
in 2017, based on a meta-analysis of the benefits and 
risks of intensive reduction of BP. They recommend 
that in elderly patients pharmacological therapy 
should be initiated at BP higher than 150 mmHg 
and aiming to a target of < 150 mm Hg. In patient 
with a history of stroke or TIA, BP target should be 
< 140 mm Hg. Such BP target can be also adopted in 
patients with high global cardiac risk after discussing 
with the patient potential benefits and risks.
It is also worth noting that the HYVET, which 
still remains the only study specifically designed to 
address hypertension in patients over 80 years of age, 
and not a sub-analysis, demonstrated the benefits of 
antihypertensive therapy (systolic BP target was <150 
mm Hg) in this age group.
Target BP values for elderly patients in various 
clinical situations proposed in the REMEDIA NT 
65+ GP, which are presented in Table IV, represent 
an attempt to balance the arguments presented in 
different guidelines, taking into account the spe-
cificity of older patients with lower haemodynamic 
adaptability, the occurrence of frailty syndrome and 
isolated systolic blood pressure, as well as the specifi-
city of a family doctor practice.
Non-pharmacological treatment
Non-pharmacological treatment of hypertension 
consists in the implementation of lifestyle changes 
that significantly reduce BP values, increase the ef-
fectiveness of pharmacological treatment and may 
reduce the risk of cardiovascular complications. Life-
style modification is the first and necessary element 
of therapy, regardless of the degree of hypertension, 
also in elderly patients.
These recommendations are not significantly dif-
ferent for patients over 65 years of age and are sum-
marized in Table V based on the 2018 ESH/ESC 
Guidelines.
In many older patients, the recommendation of 
physical exercise is difficult to implement; however, 
they should not give up physical activity, but adjust 
it to their individual abilities. It is also important that 
caution should be exercised in limiting salt intake in 
patients with dementia.
Table IV. Blood pressure treatment targets in elderly patients 
Recommendation Class of recommendation Level of evidence
In patients aged 65–80 years, it is recommended that target SBP value should be 
< 140 mm Hg, but not lower than 130 mm Hg
I A
In patients aged > 80 years, it is recommended that target SBP values should be 
< 150 mm Hg, but not lower than 130 mm Hg
II A
In patients aged > 65 years, it is recommended that target DBP should be  
< 80 mm Hg, but not lower than 70 mm Hg
I A
In patients with isolated systolic hypertension aged > 65 years, it is  
recommended that target SBP should be < 140 mm Hg and target DBP  
should not be lower than 65 mm Hg
II B
Changing well-tolerated and effective (treatment target achieved) blood pressure-
lowering therapy when patients attain 65 or 80 years, which results in new BP 
target ranges, is not recommended
III C
BP — blood pressur; SBP — systolic blood pressure; DBP — diastolic blood pressure
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Drug choice
The first-line drugs in the treatment of hypertension, 
also in the elderly, are those from five basic groups 
of antihypertensives, as indicated in American and 
European guidelines on hypertension treatment. 
However, the importance of these drug groups is 
different in older patients, which will be discussed 
below. These are: 
 — thiazides/thiazide-like diuretics;
 — b-blockers;
 — calcium antagonists;
 — angiotensin-converting enzyme inhibitors 
(ACEIs);
 — angiotensin receptor blockers (ARBs), commonly 
called sartans. 
In addition, due to the significantly increased role of 
single-pill combinations (SPCs), the importance of 
specific groups of antihypertensive drugs in current 
guidelines, i.e. 2017 AHA/ACC and 2018 ESH/ 
/ESC Guidelines, depends largely on the availability 
of SPCs including these drugs.
Thiazides, thiazide-like diuretics
Thiazides/thiazide-like diuretics are among the ba-
sic antihypertensive therapies for older patients, 
and in patients over 80 years are the drugs of choice 
(indapamide), because their use is supported by 
a lot of evidence from large clinical trials (HYVET, 
PATS [Post-stroke Antihypertensive Treatment 
Study]) indicating their beneficial role in cardio-
vascular risk prevention. Indapamide is available in 
two- and three-drug combinations, which enables 
the initiation or intensification of therapy accord-
ing to the algorithm presented below. It should 
be emphasized that the full hypotensive effect of 
thiazides/thiazide-like diuretics occurs only after 
several days of treatment. Research carried out in 
recent years has provided data showing that thi-
azide-like diuretics (chlorthalidone, indapamide) 
should be preferred among diuretic agents not only 
because of more evidence of benefits in terms of 
cardiovascular risk reduction from large clinical tri-
als, but also the low usefulness of hydrochlorothi-
azide monotherapy at currently used smaller doses 
of 12.5–25 mg (weaker and short-term hypotensive 
effect). Moreover these drugs have a more favour-
able metabolic profile.
Beta-blockers
Beta-blockers are less important in the treatment of 
uncomplicated hypertension in the elderly. However, 
they are used in this age group for treating patients 
with concomitant heart failure and coronary heart 
disease, especially those after myocardial infarction 
or with inoperable dissecting aortic aneurysm. The 
choice between vasodilating b-blocker (nebivolol, 
carvedilol) and the classical cardioselective b-block-
er (bisoprolol) is determined by the influence on 
the heart rate. The chronotropic effect is more pro-
nounced in the case of classical cardioselective beta-
blockers. Bisoprolol is the only drug of this group 
available in SPC — with dihydropiridine calcium 
antagonist (amlodipine) or ACE inhibitor (perin-
dopril).
Calcium antagonists
Apart from diuretics, calcium antagonists are also one 
of the main groups of drugs used in the treatment 
of hypertension in elderly people. Dihydropyridine 
calcium antagonists, with significantly more clinical 
evidence from large clinical trials, should be preferred, 
especially in patients with isolated systolic hyperten-
sion (Syst-Eur). Most clinical evidence from major 
clinical trials on cardiovascular risk reduction is based 
on amlodipine, which is available in many single-pill 
combinations. Due to the relatively frequent occur-
rence of lower limb oedema after amlodipine therapy, 
alternative therapy is suggested with other long-acting 
dihydropyridine calcium antagonists that are better 
tolerated, lercanidipine and lacidipine.
Table V. Recommendations for lifestyle changes in elderly patients with hypertension
Recommendation Class of recommendation Level of evidence
Reduction in the use of salt to < 5 g/day (adding salt to dishes and eating pre-
served products should be avoided)
I A
Restriction of alcohol consumption to no more than 10 g of pure ethanol in women 
and no more than 20 g of pure ethanol in men
I A
Maintaining normal body weight (BMI < 25 kg/m2) with increased consumption 
of vegetables and other food of plant origin (4–5 servings)
I A
Regular aerobic exercise (optimum > 30 min., 5–7 days per week) adjusted to 
physical fitness of elderly people
I A
Smoking cessation I B
BMI — body mass index
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ACE inhibitors and sartans
Both groups of drugs blocking the renin-angiotensin 
system are used in the treatment of hypertension in 
elderly patients with organ damage and high cardio-
vascular risk associated with ischaemic heart disease, 
heart failure, kidney disease and hypertension coex-
isting with the metabolic syndrome and/or diabetes 
mellitus, and — in combination with a thiazide-like 
diuretic — in patients after stroke. Although conclu-
sions from various meta-analyses are inconsistent, it 
appears that ACE inhibitors have some advantages 
over sartans in reducing the risk of cardiovascular 
events, while sartan therapy is associated with less 
common adverse effects. Drugs from both groups 
are widely available and used in basic two- and three-
drug (only perindopril and valsartan) SPCs.
Single-pill combinations
The role of SPCs in the treatment of hypertension 
has remarkably increased. It is reflected by the 2018 
ESH/ESC Guidelines which recommend starting 
antihypertensive therapy with drug combination, 
preferably in a SPC. Single-pill combinations are 
also preferred for treatment intensification. In el-
derly patients, due to higher target BP values recom-
mended in Europe, also in this document, SPCs will 
probably not be used as widely to initiate treatment 
as in younger patients, especially in patients with 1st 
degree hypertension. Nevertheless, the importance 
of the following three types of SPC in the treatment 
of elderly patients should be emphasized: a combi-
nation of a thiazide/thiazide-like diuretic with a di-
hydropiridine calcium antagonist, which is a basic 
combination for older patients with uncomplicated 
hypertension, and combinations of a RAS system 
blocker with a thiazide/thiazide-like diuretic or 
a dihydropiridine calcium antagonist at substandard 
doses. Among these SPCs, available are only combi-
nations based on thiazide-like diuretic indapamide, 
the most popular dihydropiridine calcium antagonist 
amlodipine and angiotensin converting enzyme in-
hibitor perindopril.
Antihypertensive treatment algorithm
The drug treatment algorithm for hypertension pre-
sented in the 2018 ESH/ESC Guidelines assumes 
almost universal application of SPC for treatment 
initiation and intensification. It seems that in older 
patients, especially those over 80 years of age, initia-
tion of drug therapy should be more cautious due to 
the higher recommended BP target. According to the 
algorithm of antihypertensive treatment presented in 
Figures 1 and 2, treatment initiation in older patients 
with 1st degree hypertension and in patients over 
80 years of age with 2nd degree hypertension should 
be based on a single drug or a SPC of two drugs in 
substandard doses.
The algorithm also takes into account that thia-
zides/thiazide-like diuretics or dihydropiridine cal-
cium antagonists are the preferred drugs for initia-
tion of antihypertensive therapy in patients over 65 
years of age, especially those with isolated systolic 
hypertension, and that the HYVET study assessing 
the indapamide-based therapy, which is the only 
study designed specifically for patients aged 80 years 
and over, and not a sub-analysis, demonstrated the 
1st degree hypertension
Monotherapy 
(thiazide-like diuretic or DHP CCB)
or SPC 
(ACEI + thiazide-like diuretic or DHP CCB 
at substandard doses 
 
Two-drug SPC at standard doses 
Three-drug SPC
2nd/3rd degree hypertension
SPC
(thiazide-like diuretic + DHP CCB 
or thiazide-like diuretic + ACEI
or + DHP CCB + ACEI)  
at standard doses 
Two-drug SPC at full doses
Three-drug SPC at full doses
BP above target values
BP above target values
Figure 1. Algorithm of antihypertensive treatment in patients aged 65–80 years. SPC — single-pill combination; ACEI — angiotensin-conver-
ting enzyme inhibitor; DHP CCB — dihydropiridine calcium antagonist
arterial hypertension 2018, vol. 22, no. 4
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benefits of antihypertensive therapy in terms of re-
duction of cardiovascular death, stroke and heart 
failure in this age group.
Individualization of antihypertensive therapy 
in patients over 65 years of age
The algorithm of antihypertensive treatment pre-
sented in the REMEDIA NT 65+ GP is intended 
for use in patients with uncomplicated hypertension. 
In the case of significant organ damage, cardiovas-
cular complications and concomitant diseases, this 
algorithm needs modification, i.e. individualization 
of antihypertensive therapy according to separate 
standards of treatment of these diseases with the use 
of drugs that also have hypotensive effect. Essentially, 
old age does not affect the principles of treatment 
individualization, which are detailed in the 2015 
PTNT Guidelines.
In the era of SPCs’ primacy, it is worth recalling 
that:
 — in patients with left ventricular hypertrophy the 
treatment associated with the greatest chance for 
disease regression is the combination of a RAS 
blocker with dihydropiridine calcium antagonist;
 — in patients after stroke a thiazide diuretic in com-
bination with an ACE inhibitor (PROGRESS) is 
recommended;
 — in patients with concomitant ischaemic heart 
disease or heart failure a combination of a beta-
blocker with an ACE inhibitor is recommended;
 — in patients with chronic kidney disease  a com-
bination of a RAS blocker with a dihydropiridine 
calcium antagonist is recomended;
 — in patients with diabetes a combination of a thia-
zide diuretic with an ACE inhibitor (ADVANCE) 
is recommended. 
All listed drug combinations are available in the 
form of SPC.
Cooperation between elderly patients 
and doctors
Poor patient/doctor cooperation, i.e. non-adherence 
to medical recommendations, is one of the impor-
tant reasons for the low effectiveness of antihyper-
tensive therapy, also in elderly patients. Therefore, 
it is the doctor’s responsibility to take actions to 
improve patient’s compliance and persistence with 
prescribed therapy from its initiation to discontin-
uation. Studies show that older patients are more 
motivated for treatment. They are characterized by 
greater therapeutic persistence, while compliance 
with recommended treatment regimes, i.e. the per-
centage of doses of drugs taken, is worse than in 
younger patients. One of the reasons of poor compli-
ance of elderly patients may be age-related memory 
problems, difficulty in understanding the dosing 
schedule, worse tolerance of normal BP values, dif-
ficulty affording prescribed medications or presence 
of concomitant diseases associated with more symp-
toms and the need for multiple medications. Hence, 
doctors need to give elderly patients more time to 
explain the dosing schedule and the importance of 
antihypertensive treatment, and sometimes to in-
volve family members or determine the economic 
status of an elderly patient.
Two changes in the guidelines for the treatment 
of hypertension presented in this document may 
improve the patient’s compliance. Adopting slightly 
higher BP targets improves older patients’ ability 
to tolerate treatment and treatment-related change 
2nd degree hypertension
Monotherapy 
(indapamide)
Two-drug SPC (based on indapamide)  
Three-drug SPC 
3rd degree hypertension
SPC
(based on indapamide)  
Two-drug SPC at full doses
Three-drug SPC at full doses
BP above target values
BP above target values
Figure 2. Algorithm of antihypertensive treatment in patients aged > 80 years. SPC — single-pill combination
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of quality of life. Also, a significant increase in the 
role of SPCs in the treatment of hypertension may 
contribute to improved compliance by reducing the 
number of pills to be taken and simplifying the dos-
ing regimens.
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